Stock Events

Stock Events

Karyopharm Therapeutics 

€1.5800
64
-€0.05-3.07% Thursday 06:03

Statistics

Day High
1.58
Day Low
1.58
52W High
9.2
52W Low
1.58
Volume
-
Avg. Volume
-
Mkt Cap
35.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2025
Q1 2026
Q2 2026
Next
-4.81
-3.48
-2.15
-0.82
Expected EPS
-0.81654936
Actual EPS
N/A

Financials

-133.3%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
126.49MRevenue
-168.62MNet Income

Analyst Ratings

10.05Average Price Target
The highest estimate is 21.25.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 25K0.MU. It's not an investment recommendation.
Apple
14
AAPL
Microsoft
14
MSFT
Amazon
13
AMZN
NVIDIA
11
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Karyopharm's focus on cancer therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the oncology and hematology market, directly competing with Karyopharm's cancer drug offerings.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse range of cancer drugs that compete with Karyopharm's therapies in multiple myeloma and other cancers.
Merck
MRK
Mkt Cap366B
Merck & Co. is a leading pharmaceutical company with a strong lineup of cancer drugs that compete with Karyopharm's products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio, including treatments for conditions that Karyopharm's drugs target.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the oncology market with a focus on cancer treatments, including therapies that could be in direct competition with Karyopharm's products.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a significant presence in the oncology sector, with drugs that compete against Karyopharm's offerings in cancer treatment.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of cancer treatments, including therapies that directly compete with Karyopharm's products.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, has a portfolio of cancer drugs that compete with Karyopharm's therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, though more focused on biotechnology, has been expanding its oncology portfolio, potentially competing with Karyopharm's cancer treatments.

About

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Show more...
CEO
Richard A. Paulson
Employees
228
Country
United States
ISIN
US48576U2050
WKN
000A40YLC

Listings

STU
DE
25K0.STU
MU
DE
25K0.MU
BOATS
BOATS
KPTI.BOATS
XNAS
US
KPTI

0 Comments

Share your thoughts

FAQ

What is Karyopharm Therapeutics stock price today?▼
The current price of 25K0.MU is €1.58 EUR — it has decreased by -3.07% in the past 24 hours. Watch Karyopharm Therapeutics stock price performance more closely on the chart.
What is Karyopharm Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Karyopharm Therapeutics stocks are traded under the ticker 25K0.MU.
What is Karyopharm Therapeutics market cap?▼
Today Karyopharm Therapeutics has the market capitalization of 35.84M
When is the next Karyopharm Therapeutics earnings date?▼
Karyopharm Therapeutics is going to release the next earnings report on October 29, 2026.
What were Karyopharm Therapeutics earnings last quarter?▼
25K0.MU earnings for the last quarter are -2.01 EUR per share, whereas the estimation was -1.19 EUR resulting in a -69.14% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Karyopharm Therapeutics revenue for the last year?▼
Karyopharm Therapeutics revenue for the last year amounts to 126.49M EUR.
What is Karyopharm Therapeutics net income for the last year?▼
25K0.MU net income for the last year is -168.62M EUR.
How many employees does Karyopharm Therapeutics have?▼
As of September 04, 2026, the company has 228 employees.
In which sector is Karyopharm Therapeutics located?▼
Karyopharm Therapeutics operates in the Health & Wellness sector.
When did Karyopharm Therapeutics complete a stock split?▼
The last stock split for Karyopharm Therapeutics was on February 26, 2025 with a ratio of 1:15.
Where is Karyopharm Therapeutics headquartered?▼
Karyopharm Therapeutics is headquartered in NEWTON, United States.